Pharmabiz50m
Biologit boosts patient safety with automated local literature monitoring solution for non-indexed sources
Biologit boosts patient safety with automated local literature monitoring solution for non-indexed sources: Dublin, Ireland Friday, April 4, 2025, 18:00 Hrs [IST] Biologit, a spec ...
Pharmabiz1h
The Good Bug presents clinically proven natural GLP-1 weight loss solution amid rising obesity rates in India
The Good Bug presents clinically proven natural GLP-1 weight loss solution amid rising obesity rates in India: Our Bureau, Bengaluru Friday, April 4, 2025, 17:20 Hrs [IST] The Goo ...
Pharmabiz1h
Helsinn Group submits new innovative formulation of Akynzeo to European Medicines Agency
Helsinn Group submits new innovative formulation of Akynzeo to European Medicines Agency: Lugano, Switzerland Friday, April 4, 2025, 17:00 Hrs [IST] Helsinn Group, a global pharma ...
Pharmabiz2h
Sova Health launches advanced microbiome tests & evidence-based precision supplements
Sova Health launches advanced microbiome tests & evidence-based precision supplements: Our Bureau, Bengaluru Friday, April 4, 2025, 16:50 Hrs [IST] Sova Health, India’s first fu ...
Pharmabiz2h
Aon reports rising healthcare costs with India among the fastest-growing medical markets
Aon reports rising healthcare costs with India among the fastest-growing medical markets: Our Bureau, Bengaluru Friday, April 4, 2025, 16:40 Hrs [IST] Aon’s Global Medical Trend ...
Pharmabiz2h
Kapadia Hospital joins India’s first AI surgery revolution with MISSO, hailed by PM Modi
Kapadia Hospital joins India’s first AI surgery revolution with MISSO, hailed by PM Modi: Our Bureau, Mumbai Friday, April 4, ...
Pharmabiz2h
Vividion Therapeutics doses first patient in phase I study of RAS-PI3Ka inhibitor to treat advanced solid tumours
San Diego, California Friday, April 4, 2025, 16:00 Hrs [IST] ...
Pharmabiz3h
Abbott introduces next-generation delivery system to streamline electrode placement during dorsal root ganglion stimulator implantations
Abbott Park, Illinois Friday, April 4, 2025, 15:00 Hrs [IST] ...
Pharmabiz4h
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases
US FDA grants orphan drug designation to Sanofi’s rilzabrutinib, an oral, reversible BTK inhibitor for two rare diseases: Paris Friday, April 4, 2025, 14:00 Hrs [IST] The US Foo ...
Pharmabiz5h
MultiOmic Health inks MoU with Alloy Therapeutics to discover and develop renal tissue-targeting drugs
MultiOmic Health inks MoU with Alloy Therapeutics to discover and develop renal tissue-targeting drugs: London Friday, April 4, 2025, 13:00 Hrs [IST] MultiOmic Health Limited, an ...
Pharmabiz6h
CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease
CHMP recommends approval for Averoa’s Xoanacyl, an oral therapy for chronic kidney disease: Grenoble, France Friday, April 4, 2025, 12:00 Hrs [IST] Averoa, a biopharmaceutical c ...
Pharmabiz7h
Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint
Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...